Minocycline Clinical Trial
Official title:
Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment
Verified date | February 2018 |
Source | German Parkinson Study Group (GPS) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study Hypothesis:
- Does a treatment with Minocycline of 2 x daily 2 x 50 mg effect the progression of clinical
symptoms and diagnosis in patients with MSA?
Background and Rationale:
- The Parkinson-Syndrome which is characterised by the clinical triad akinesis, rigor and
passive tremor, is caused by Parkinson's disease (PD) in about 70 % of the cases (Oertel
et al., 2003). However, beside the Parkinson's disease there are several, to some extent
rare, so-called atypical Parkinson's syndromes. The two most frequent of these atypical
Parkinson-Syndromes are the
- Multi-System-Atrophy (MSA) and the Progressive Supranuclear Palsy (PSP). Due to the
often much varying courses and since they are not well known, these diseases are
frequently diagnosed late or not diagnosed at all. Nevertheless, an early diagnosis is
substantial for further treatment, since the prognosis and therapy of atypical Parkinson
Syndromes differ essentially from those of PD. Whereas the neuronal death of cells in PD
is restricted essentially to the Substantia nigra, a dominant destruction of neurons in
brain stem, Cerebellum and Striatum additionally happens in cases of MSA and PSP.
- Up to now no adequate treatment strategies are at disposal. Initially the giving of
L-Dopa can lead to an improvement for < 10% of the patients only.
- Minocycline is an antibiotic belonging to the group of the Tetracyclines.
- Recently, it could be demonstrated that Minocycline has a neuroprotective impact besides
the anti-inflammatory impact.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility |
Inclusion Criteria: - age = 40 and <= 75 years - Diagnosis of MSA-P in accordance with consensus criteria (Gilman et al., 1999; appendix) - UMSARS IV <= 3 - Patient must be capable of understanding informed consent - Written consent to participation in the study Exclusion Criteria: - Diseases associated with a demential syndrome - Dimming of consciousness - Any other chronical inflammatory disease (Crohn's disease, ulcerative colitis, C.a. hepatitis, C.a. pancreatitis) - Any malignant tumour disease - Chronical alcohol addiction - Severe Diabetes mellitus Type I and II (HbA1c > 8 %) - AV-Block = 2nd degree - Atrial flutter, atrial fibrillation - Tachycardia (> 100 bpm) - Bradycardia (< 60 bpm) - High-blood pressure (systolic > 180 mm Hg, diastolic: > 110 mg HG) - Heart insufficiency (NYHA >2) - Pericarditis, pericardial effusion - Heart attack within the last six months before inclusion in the study, ACVB, C.a. myocarditis - Severe kidney insufficiency (Creatinine >3 mg/dl; Urea > 150 mg/dl) - Hepatic insufficiency (GOT > 3 x ULN; GPT > 3 x ULN) - Ulcer disease - Pneumonia, meningitis within 12 weeks before inclusion into study - Any immunosuppressive or cytotoxic therapy within the last year before inclusion in study - Any antibacterial and antiviral therapy within the last six weeks before inclusion in the study - Any systemic fungal infection within the last year before inclusion in the study - Any positive family anamnesis for autoimmune diseases - Pregnancy or nursing - Severe psychiatric disease within the last six months requiring hospitalisation, attempted suicide in the anamnesis, florid psychosis - Seizure disorder - Concomitant taking of the following drugs: Riluzole, Carbamazepine, Phenytoine, Primidone, Colestyramine, activated charcoal, cumarin, Cyclosporine, Methotrexate, Methoxyflurane, Theophylline, Phenobarbital; or drug classes: Antacids (containing Al, Mg, Ca), Retinoids, Digitalis Glycosides - Known hypersensitivity against Minocycline or other Tetracyclines - Simultaneous participation in another clinical trial |
Country | Name | City | State |
---|---|---|---|
Austria | Neurologische Klinik der Universität Innsbruck | Innsbruck | |
Germany | Neurologische Poliklinik, Charité Campus Virchow | Berlin | |
Germany | Neurologische Universitätsklinik am Klinikum der Friedrich-Wilhelm-Universität Bonn | Bonn | |
Germany | Neurologische Universitätsklinik, Universitätsklinikum Carl-Gustav-Carus der Technischen Universität Dresden | Dresden | Sachsen |
Germany | Universitätsklinikum Heidelberg, Neurologische Klinik | Heidelberg | Baden-Württemberg |
Germany | Paracelsus-Elena-Klinik | Kassel | Hessen |
Germany | Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Neurologie | Kiel | Schleswig-Holstein |
Germany | Neurologische Klinik der Philipps-Universität Marburg | Marburg | Hessen |
Germany | Universitätsklinikum Tübingen, Neurologische Klinik | Tübingen | Baden-Württemberg |
Germany | Neurologische Klinik am Klinikum der BJM-Universität | Würzburg | Bayern |
Lead Sponsor | Collaborator |
---|---|
German Parkinson Study Group (GPS) | Competence Network on Parkinson's Disease, European MSA-Study Group, Federal Institute of Education and Sience |
Austria, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in motor function: Difference between the UMSARS II baseline score and the UMSARS II score 48 weeks after start of therapy | |||
Secondary | Difference between the UMSARS II baseline score and the UMSARS II score 24 weeks after start of therapy | |||
Secondary | Difference between the UMSARS I, III, IV baseline score and the UMSARS I, III, IV score 24 and 48 weeks after start of therapy | |||
Secondary | Difference between the UPDRS I-III baseline score and the UPDRS I-III score 24 and 48 weeks after start of therapy | |||
Secondary | Difference between the SF-12 baseline score and the SF-12 score 24 and 48 weeks after start of therapy | |||
Secondary | Difference between the EQ-5D baseline score and the EQ-5D score 24 and 48 weeks after start of therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00409747 -
Minocycline to Treat Childhood Regressive Autism
|
Phase 4 | |
Recruiting |
NCT05474950 -
Minocycline Treatment for Cystoid Macular Edema
|
Phase 1/Phase 2 | |
Completed |
NCT04210713 -
Neuroimmune Dysfunction in Alcohol Use Disorder
|
Phase 1 | |
Recruiting |
NCT05512910 -
Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)
|
Phase 4 | |
Recruiting |
NCT05474729 -
Minocycline for Chronic Autoimmune Uveitis
|
Phase 1/Phase 2 |